Sugemalimab Offers Another Option in Unresectable NSCLC : vi

A new immunotherapy from China may offer another option for post-chemoradiotherapy treatment in patients with unresectable with stage III non-small cell lung cancer.

Related Keywords

Guangzhou , Guangdong , China , Charlottesville , Virginia , United States , Austria , Vienna , Wien , Long Wu , Hubei , Jilin , University Of Virginia , Lindaw Martin , Bristol Meyers Squibb , Eli Lilly , Cstone Pharmaceuticals , Boehringer Ingelheim , Guangdong Lung Cancer Institute , Novartis , Development Program Of China , Pfizer , Astrazeneca , National Key Research , Lancet Oncology , World Conference , Lung Cancer , Guangdong Provincial People , Medscape Medical , Development Program , Ung Carcinoma , Ancer Lung , Non Small Cell Lung Cancer , Nsclc , Chemotherapy , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Biologic Therapy , Immunotherapy , Activism , Activist , Biventricular Pacing , Shiv , Cardiac Resynchronization Therapy , Art , Drug Development , Histology , Cmon ,